Calliditas Therapeutics' 2023 Annual Report Published
- None.
- None.
For further information, please contact:
Åsa Hillsten, Head of IR & Sustainability, Calliditas
Tel.: +46 76 403 35 43, Email: asa.hillsten@calliditas.com
This information is information that Calliditas Therapeutics AB is obliged to make public pursuant to the Securities Markets Act. The information was sent for publication, through the agency of the contact persons set out above, on April 24, 2024, at 7:00 p.m. CET.
About Calliditas
Calliditas Therapeutics is a biopharma company headquartered in
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding the development of Calliditas' pipeline. The words "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "project," "potential," "continue," "target," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties, and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, any related to Calliditas' business, operations, clinical trials, intellectual property of the NEFECON franchise globally, competition from other companies, pipeline development, revenue and product sales projections or forecasts, 2024 revenue guidance and other risks identified in the section entitled "Risk Factors" in Calliditas' reports filed with the Securities and Exchange Commission. Calliditas cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Calliditas disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent Calliditas' views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Calliditas Annual Report 2023 | |
https://mb.cision.com/Public/16574/3967336/9a2538e7ee7d898d.pdf | Annual Report 2023 Eng |
View original content:https://www.prnewswire.com/news-releases/calliditas-therapeutics-2023-annual-report-published-302126456.html
SOURCE Calliditas Therapeutics
FAQ
Where can I find Calliditas Therapeutics' 2023 Annual Report?
What is the ticker symbol for Calliditas Therapeutics?
Who is the Head of IR & Sustainability at Calliditas Therapeutics?
When was the Annual Report for 2023 released by Calliditas Therapeutics?
What regulatory act requires Calliditas Therapeutics to publish financial information?
